Risk of serious adverse events, including those that may be complications of the common cold · adults and children with colds and/or upper respiratory infections
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of colds developed Duration of · adults and children without colds
1 finding from 1 review
Duration of cold symptoms (days) · adults and children without colds
1 finding from 1 review
Standardised mean global symptom severity Duration of · adults and children without colds
1 finding from 1 review
Risk of adverse events, including those that may be due to zinc supplements Duration of · adults and children without colds
1 finding from 1 review
Risk of serious adverse events, including those that may be complications of the common cold Duration of · adults and children without colds
1 finding from 1 review
Duration of cold symptoms (days) · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Risk of continuing colds at study end Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Standardised mean global symptom severity Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical remission (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical improvement (Mayo score) (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes clinical improvement (Mayo score) (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Quality of life · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes total adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Reduction in exposure to asbestos · asbestos workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asbestos concentration reduction · asbestos workers
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Asbestos exposure after doffing · asbestos workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Donning and doffing errors · asbestos workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · asbestos workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asbestos concentration · asbestos workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found